
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.
The virtual trip
The Virtual Trip is filling your table full of psychedelic sessions for your holiday week. Grab your laptop or phone, a warm drink, and your stretchy pants, and get ready to enjoy our largest video release yet
“I'm not allowed to touch the mushrooms”: 5 Questions for Oregon-based facilitator Josh Goldstein
Goldstein helps train other facilitators and guides psilocybin sessions with clients in Bend, Oregon ... We spoke with Goldstein about his role as a licensed facilitator, and how it differs from his work in the underground.
When the trial ends: The case for post-trial provisions in clinical psychedelic research
We show how conceiving of post-trial provision as an integral site of the research process, and an appropriate destination for research funding, will serve to develop the infrastructure necessary for the post-legalisation psychedelic medicine ecosystem.
Psychedelic-assisted psychotherapy: Where is the psychotherapy research?
PAP is a highly unique and transdisciplinary intervention, and future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.
Psychiatric risks for worsened mental health after psychedelic use
We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use, and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.
Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study
Trait mindfulness, specifically description and non-judging of inner experience, was increased, and neuroticism was decreased after 4 weeks of MD compared to baseline. The remaining personality traits remained unchanged. Using conventional medication and/or having comorbid diagnoses did not change the MD-induced effects on mindfulness and personality traits after 4 weeks. Conclusion: MD induced changes in otherwise stable traits. Future placebo-controlled studies are warranted to confirm whether these changes occur in a controlled setting.
Ketamine for depression - Knowns, unknowns, possibilities, barriers, and opportunities
Ketamine has the potential to change our approach to the clinical management of depression if knowledge, attitudinal, and regulatory barriers can be overcome, and if risks related to comorbidities and concurrent medications are addressed by close supervision.
Insights, life changes and lifestyle changes reported by individuals consuming ayahuasca in naturalistic settings: Nature, frequency and associations with mental health and wellbeing
Insights and subsequent life and lifestyle changes appear to have a central role in the transformative effects reported by individuals consuming ayahuasca, with these occurring across contexts of use and demographic groups.
Does MDMA have treatment potential in sexual dysfunction? A systematic review of outcomes across the female and male sexual response cycles
Our findings suggest that MDMA generally increases sexual desire and intensifies orgasm when achieved. While producing conflicting evidence on sexual arousal in both sexes, MDMA may impair erectile and ejaculatory function in men.
Psychological and physiological effects of extended DMT
Taken together, these findings demonstrate the safety and effectiveness of continuous IV DMT administration, laying the groundwork for the further development of this method of administration for basic and clinical research.
Randomized trial of ketamine masked by surgical anesthesia in patients with depression
Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials